120 related articles for article (PubMed ID: 7705381)
1. Effect on collagen metabolism of thrombolytic therapy with tissue-plasminogen activator. A randomized, placebo-controlled study.
Høst NB; Stoltenberg MB; Jensen LT; Larsen OG; Aurup P
Eur J Clin Invest; 1995 Jan; 25(1):15-8. PubMed ID: 7705381
[TBL] [Abstract][Full Text] [Related]
2. Thrombolytic therapy of acute myocardial infarction alters collagen metabolism.
Høst NB; Hansen SS; Jensen LT; Husum D; Nielsen JD
Cardiology; 1994; 85(5):323-33. PubMed ID: 7850822
[TBL] [Abstract][Full Text] [Related]
3. Changes in interstitial collagen metabolism during acute myocardial infarction treated with streptokinase or tissue plasminogen activator.
Peuhkurinen K; Risteli L; Jounela A; Risteli J
Am Heart J; 1996 Jan; 131(1):7-13. PubMed ID: 8554022
[TBL] [Abstract][Full Text] [Related]
4. Thrombolytic therapy with streptokinase stimulates collagen breakdown.
Peuhkurinen KJ; Risteli L; Melkko JT; Linnaluoto M; Jounela A; Risteli J
Circulation; 1991 Jun; 83(6):1969-75. PubMed ID: 2040049
[TBL] [Abstract][Full Text] [Related]
5. Changes of collagen metabolism predict the left ventricular remodeling after myocardial infarction.
Radovan J; Vaclav P; Petr W; Jan C; Michal A; Richard P; Martina P
Mol Cell Biochem; 2006 Dec; 293(1-2):71-8. PubMed ID: 16933032
[TBL] [Abstract][Full Text] [Related]
6. Collagen scar formation after acute myocardial infarction: relationships to infarct size, left ventricular function, and coronary artery patency.
Uusimaa P; Risteli J; Niemelä M; Lumme J; Ikäheimo M; Jounela A; Peuhkurinen K
Circulation; 1997 Oct; 96(8):2565-72. PubMed ID: 9355895
[TBL] [Abstract][Full Text] [Related]
7. [t-PA in thrombolytic therapy of acute myocardial infarct].
Rutsch W; Schmutzler H
Herz; 1994 Dec; 19(6):336-52. PubMed ID: 7843690
[TBL] [Abstract][Full Text] [Related]
8. Seromarkers of collagen I and III metabolism in active Crohn's disease. Relation to disease activity and response to therapy.
Kjeldsen J; Schaffalitzky de Muckadell OB; Junker P
Gut; 1995 Dec; 37(6):805-10. PubMed ID: 8537052
[TBL] [Abstract][Full Text] [Related]
9. Effect of coronary revascularization on serum collagen biomarkers and left ventricular remodeling in patients with acute myocardial infarction.
Ren HZ; Zhang XS; Wang LX
Heart Lung; 2012; 41(4):344-9. PubMed ID: 22054723
[TBL] [Abstract][Full Text] [Related]
10. New developments in thrombolytic therapy.
Collen D; Gold HK
Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
[TBL] [Abstract][Full Text] [Related]
11. The aminoterminal propeptide of type III procollagen provides new information on prognosis after acute myocardial infarction.
Høst NB; Jensen LT; Bendixen PM; Jensen SE; Koldkjaer OG; Simonsen EE
Am J Cardiol; 1995 Nov; 76(12):869-73. PubMed ID: 7484822
[TBL] [Abstract][Full Text] [Related]
12. Serum carboxy terminal propeptide of type I procollagen to amino terminal propeptide of type III procollagen ratio is a better indicator than each single propeptide and 7S domain type IV collagen for progressive fibrogenesis in chronic viral liver diseases.
Lin DY; Chu CM; Sheen IS; Liaw YF
Dig Dis Sci; 1995 Jan; 40(1):21-7. PubMed ID: 7821112
[TBL] [Abstract][Full Text] [Related]
13. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial.
Cannon CP; McCabe CH; Diver DJ; Herson S; Greene RM; Shah PK; Sequeira RF; Leya F; Kirshenbaum JM; Magorien RD
J Am Coll Cardiol; 1994 Dec; 24(7):1602-10. PubMed ID: 7963104
[TBL] [Abstract][Full Text] [Related]
14. Long-lasting depression of the factor XII-dependent fibrinolytic system in patients with myocardial infarction undergoing thrombolytic therapy with recombinant tissue-type plasminogen activator: a randomized placebo-controlled study.
Munkvad S; Jespersen J; Gram J; Kluft C
J Am Coll Cardiol; 1991 Mar; 17(4):957-62. PubMed ID: 1900313
[TBL] [Abstract][Full Text] [Related]
15. Propeptide levels of type III and type I procollagen in the serum and bronchoalveolar lavage fluid of patients with pulmonary sarcoidosis.
Lammi L; Kinnula V; Lähde S; Risteli J; Pääkkö P; Lakari E; Ryhänen L
Eur Respir J; 1997 Dec; 10(12):2725-30. PubMed ID: 9493651
[TBL] [Abstract][Full Text] [Related]
16. Rebound increase of plasminogen activator inhibitor type I after cessation of thrombolytic treatment for acute myocardial infarction is independent of type of plasminogen activator used.
Genser N; Lechleitner P; Maier J; Dienstl F; Artner-Dworzak E; Puschendorf B; Mair J
Clin Chem; 1998 Feb; 44(2):209-14. PubMed ID: 9474013
[TBL] [Abstract][Full Text] [Related]
17. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial.
Cannon CP; McCabe CH; Henry TD; Schweiger MJ; Gibson RS; Mueller HS; Becker RC; Kleiman NS; Haugland JM; Anderson JL
J Am Coll Cardiol; 1994 Apr; 23(5):993-1003. PubMed ID: 8144799
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of collagen turnover biomarkers in cardiac resynchronization therapy: A subanalysis of the TRUST CRT randomized trial population.
Sokal A; Lenarczyk R; Kowalski O; Mitrega K; Pluta S; Stabryla-Deska J; Streb W; Urbanik Z; Krzeminski TF; Kalarus Z
Heart Rhythm; 2016 May; 13(5):1088-1095. PubMed ID: 26776557
[TBL] [Abstract][Full Text] [Related]
19. Plasma and tissue levels of collagen types I and III markers in patients with abdominal aortic aneurysms.
Treska V; Topolcan O
Int Angiol; 2000 Mar; 19(1):64-8. PubMed ID: 10853688
[TBL] [Abstract][Full Text] [Related]
20. Effects of lipoprotein (a) on success rate of thrombolytic therapy in acute myocardial infarction.
von Hodenberg E; Kreuzer J; Hautmann M; Nordt T; Kübler W; Bode C
Am J Cardiol; 1991 Jun; 67(16):1349-53. PubMed ID: 1828324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
